Loading financial data...

LakeShore Biopharma Co., Ltd. (LSBCF) Financial Statements | Global Financial Data

LakeShore Biopharma Co., Ltd.

LSBCFSEC EDGAR

Pharmaceutical Preparations(E9)CIK: 1946399

Concept	FY2025	FY2024	FY2023
Revenues	$687.2M	$502.9M	$257.0M
Cost of Revenue	$153.4M	$117.1M	$59.7M
Gross Profit	$533.8M	$385.9M	$197.4M
Research and Development Expense	$318.7M	$211.2M	$94.4M
Operating Expenses	$673.2M	$504.8M	$323.2M
Operating Income (Loss)	-$139.4M	-$119.0M	-$125.8M
Nonoperating Income (Expense)	-$5.0M	$17.9M	-$48.5M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$144.3M	-$101.1M	-$174.4M
Income Tax Expense (Benefit)	$1.1M	$4.9M	$17.5M
Net Income (Loss) Attributable to Parent	-$145.5M	-$106.0M	-$191.8M
Earnings Per Share, Basic

Concept	FY2025	FY2024	FY2023
Assets	$1.5B	$1.7B	$1.4B
Assets, Current	$903.2M	$1.0B	$764.8M
Cash and Cash Equivalents, at Carrying Value	—	—	$370.4M
Accounts Receivable, after Allowance for Credit Loss, Current	$444.2M	$463.1M	$308.6M
Inventory, Net	$203.4M	$185.4M	$166.5M
Liabilities	$927.8M	$991.3M	$770.5M
Liabilities, Current	$802.2M	$658.8M	$475.9M
Long-term Debt	$99.0M	$293.8M	—
Accounts Payable, Current	$67.8M	$80.4M	$30.8M
Stockholders' Equity Attributable to Parent	-$699.0M	-$508.9M	-$847.3M

Concept	FY2025	FY2024	FY2023
Net Cash Provided by (Used in) Operating Activities	-$182.5M	-$173.5M	-$246.6M
Net Cash Provided by (Used in) Investing Activities	-$57.0M	-$298.9M	-$104.2M
Net Cash Provided by (Used in) Financing Activities	$317.4M	$364.6M	$739.3M
Payments to Acquire Property, Plant, and Equipment	$52.8M	$295.3M	$104.9M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)